Clinical Trial Update: The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of iguratimod and danazol for steroid-resistant or relapsed immune thrombocytopenia (ITP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Danazol (danazol)
• Iguratimod (iguratimod)

Snippet

Sponsor: Peking University People's Hospital | Conditions: ITP, Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN